Prescient Therapeutics Investor Briefing – 4 November
Prescient Therapeutics (ASX: PTX) Webcast Replay
Prescient Therapeutics (ASX:PTX) are focused on developing novel, personalised therapies for a range of cancers through universal CAR-T and targeted therapies.
As a part of our ‘The Insiders’ series, CEO Steven Yatomi-Clarke provides valuable insights to the company, its key markets and industry, and future prospects.
Recorded on 4 November 2020 at 12pm (AEDT).
FEATURE SPEAKERS
Steven Yatomi-Clarke
Chief Executive Officer - Prescient Therapeutics (ASX: PTX)
Prescient Therapeutics (ASX:PTX) are focused on developing novel, personalised therapies for a range of cancers. Prescient’s universal CAR-T and targeted therapies are both personalised medicine approaches which seek to improve patient outcomes, whilst also providing new tools for clinicians in combating cancer. Prescient has a broad pipeline of personalised cancer treatments, comprising CAR-T and targeted therapies, and has licensed technologies from and in collaboration with world-leading cancer centers in the US and Australia.
